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Manymalignant characteristics of cancer cells are regulated through pathways induced by the tyrosine kinase activity
of the epidermal growth factor receptor (EGFR). Herein, we show that besides directly affecting the biology of cancer
cellsper se, EGFRalso regulates the primary tumormicroenvironment. Specifically, our findingsdemonstrate that both
the expression and signaling activity of EGFR are required for the induction of a distinct intratumoral vasculature
capable of sustaining tumor cell intravasation, a critical rate-limiting step in the metastatic cascade. An intravasation-
sustaining mode of intratumoral angiogenic vessels depends on high levels of tumor cell EGFR and the interplay
between EGFR-regulated production of interleukin 8 by tumor cells, interleukin-8–induced influx of tumor-infiltrating
neutrophils delivering their unique matrix metalloproteinase-9, and neutrophil matrix metalloproteinase-9–dependent
release of the vascular permeability and endothelial growth factor, VEGF. Our data indicate that through VEGF-
mediated disruption of endothelial layer integrity and increase of intratumoral vasculature permeability, EGFR activity
significantly facilitates active intravasation of cancer cells. Therefore, this study unraveled an important but overlooked
function of EGFR in cancer, namely, its ability to create an intravasation-sustaining microenvironment within the
developing primary tumor by orchestrating several interrelated processes required for the initial steps of cancer
metastasis through vascular routes. Our findings also suggest that EGFR-targeted therapies might be more effective
when implemented in cancer patients with early-staged primary tumors containing a VEGF-dependent angiogenic
vasculature. Accordingly, early EGFR inhibition combined with various anti-VEGF approaches could synergistically
suppress tumor cell intravasation through inhibiting the highly permeable angiogenic vasculature induced by EGFR-
overexpressing aggressive cancer cells.
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The epidermal growth factor receptor (EGFR) is a potent tyrosine
kinase, which through downstream signaling networks regulates such
basic cell functions as proliferation, chemotactic migration, invasion,
and avoidance of apoptosis [1,2]. Elevated expression and constitutive
activity of EGFR have been strongly associated with poor prognosis in
many types of cancer, prompting the design of highly specific and
potent EGFR inhibitors to control tumor growth and metastasis
[3–5]. Those inhibitors include anti-EGFR monoclonal antibodies
(mAbs) directed against the extracellular domain of the EGFR and
small molecule tyrosine kinase inhibitors directed against the catalytic
domain of the EGFR [6,7]. Currently, EGFR-targeted therapies are
implemented or considered as an additional line of anticancer
treatments in patients with non–small-cell lung cancer, pancreaticcancer, head and neck cancer, colorectal cancer, and malignant
gliomas [8–13]. However, the somewhat modest clinical success of
EGFR inhibitors [2,9,11,14–16] compared with their performance in
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fostering the malignant behavior of tumor cells, the enhanced activity
of EGFR might also facilitate cancer progression by regulating the
primary tumor microenvironment, especially during the early steps of
tumor development and tumor dissemination.
Herein, we have proposed that besides direct regulation of tumor cell
proliferation, migration and invasion, cancer cell–expressed EGFR can
also regulate the production of distinct molecules involved in the
establishment and modification of the tumor microenvironment.
Among those molecules are vascular endothelial growth factor (VEGF),
the major angiogenic factor [24,25], and interleukin 8 (IL-8), the major
attractant for tumor-infiltrating neutrophils [26,27], the inflammatory
cell type playing a critical early role in tumor angiogenesis and finally
gaining the appreciation it deserves in cancer research [28–33].
Therefore, cancer cell–expressed EGFR can serve as an important
regulator of tumor angiogenesis and angiogenesis-dependent tumor cell
dissemination, including the intravasation step, i.e., the active entry of
tumor cells into the vasculature.
In this study, we employed the high- and low-disseminating
variants (hi/diss and lo/diss) of three distinct human tumor types,
including HT-1080 fibrosarcoma, PC-3 prostate carcinoma, and
HEp-3 head and neck carcinoma. The hi/diss and lo/diss variants of
each tumor cell type possess similar tumorigenic and colonization
capacities but manifest a substantial, 50- to 100-fold differential in
their intravasation potential [34–37]. Notably, all three hi/diss
variants express substantially higher levels of EGFR compared with
the corresponding lo/diss counterparts, suggesting a specific role of
EGFR in the intravasation process. By silencing EGFR in hi/diss
tumor variants and comparing their fate in the spontaneous versus
experimental metastasis models, we demonstrated the specific
involvement of tumor cell EGFR in the early steps of the metastatic
cascade. Furthermore, we showed that enhanced expression and
activity of tumor cell EGFR contribute to spontaneous metastasis
through facilitating the structural development of intratumoral
angiogenic blood vessels required for the process of intravasation.
To functionally analyze the specific contribution of EGFR to
intravasation, we used the HT-hi/diss cells in a microtumor model that
uniquely allows to determine the actual numbers of intravasated tumor
cells which escaped from the primary tumor and entered the circulation,
and simultaneously to conduct quantitative analyses of the entire
intratumoral vasculature of individual microtumors [37,38]. In this
model, several microtumors are initiated from collagen-embedded
tumor cells grafted on the highly vascularized chorioallantoicmembrane
(CAM) of chick embryos incubated ex ovo. In 4 to 5 days, robust
angiogenic vasculature develops within growing CAM microtumors,
facilitating intratumoral intravasation and vascular dissemination of
aggressive cancer cells, which are quantified by a real-time polymerase
chain reaction (PCR) in the distal portions of the CAM. Furthermore,
the accessibility of CAM vessels for inoculations of fluorescent lectin to
stain endothelial cells and for accurate injections of fluorescent dextrans
to assess the permeability of tumor vasculature makes this model
invaluable for quantification of intravasation along with the quantitative
analyses of the microarchitecture and permeability of intratumoral
vasculature [37,38]. In conjunction with the inhibition of EGFR
expression or its activity, this microtumor model system has allowed us
to demonstrate that EGFR regulates the efficiency of tumor cell
intravasation and that EGFR activity determines such critical
characteristics of the intratumoral angiogenic vessels as their micro-
architecture and functional integrity.In this study, we have illuminated a novel mechanism by which
tumor cell EGFR mediates tumor cell dissemination through
orchestrating the development of an intravasation-sustaining vascula-
ture within the primary tumor. These EGFR-mediated induction and
maintenance of intratumoral angiogenic vessels permeable for tumor
cells involve IL-8–induced influx of tumor-infiltrating neutrophils
delivering a unique form of matrix metalloproteinase (MMP)-9, known
to catalytically release angiogenesis-inducing VEGF, which is also a
powerful regulator of vascular permeability. Therefore, our study has
established an important link between the enhanced activity of EGFR
in human tumor cells possessing high dissemination potential and the
EGFR-induced molecular cross talk between IL-8, neutrophil MMP-9,
and MMP-9–released VEGF, evoking within the primary tumor the
development of a distinct, intravasation-sustaining vasculature.
Materials and Methods
Reagents
Rabbit antibodies specific for human EGFR (2646) and
phospho-EGFR at Y1068 (1727-1) were purchased fromCell Signaling
Technology Inc. (Danvers, MA) and Epitomics (Burlingame, CA),
respectively. Anti-human MMP-9 murine mAbs were generated in our
laboratory. Anti-tubulin mouse mAb 10D8 was from Biolegend (San
Diego, CA). Horseradish peroxidase–conjugated anti-rabbit antibody
(115-000-003) and anti-mouse antibody (115-035-003) were obtained
from Jackson Laboratory (Sacramento, CA). EGFR-specific tyrosine
kinase inhibitor erlotinib (sc-202154) was purchased from Santa Cruz
(Dallas, TX). Recombinant human VEGF (AF-100-20A) was obtained
from Peprotech (Rocky Hill, NJ). Human neutrophil MMP-9 was
purified as described [39].
Cell Lines and Culture Conditions
HT-lo/diss and HT-hi/diss variants were generated by in vivo
selection for correspondingly low and high levels of intravasation [34]
from the original human fibrosarcoma HT-1080 cell line (ATCC,
Manasass, VA). The HT-hi/diss cells were additionally transfected
with GFP. HEp-hi/diss cells are derivatives of the original human
head and neck epidermoid carcinoma, HEp-3, initially described in
[40] and recently in [37]. PC-hi/diss cells have been generated from
the original human prostate carcinoma cell line PC-3 as described
[36]. Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS (D-10).
EGFR Silencing and Inhibition of EGFR Activity
Small interfering RNA (siRNA) against human EGFR (a pool of three
EGFR-specific constructs, sc-29301) and nonsilencing control siRNA
(sc-37007) were purchased from Santa Cruz (Dallas, TX). The day before
siRNA transfection, the cells were plated in D-10 without antibiotics at
concentrations resulting in 70% to 80% confluence the following day.
Transfections were performed with 50 nM siRNA and Lipofectamine
2000 or RNAiMax (Life Technologies, Grand Island, NY), according to
the manufacturer’s instructions. After an overnight incubation, the
siRNA-treated cells were detached, washed in D-10 and serum-free-
DMEM, resuspended in serum-free-DMEM, and used in the various
assays. EGFR activity was inhibited by erlotinib, which was added to
tumor cells or primary microtumors at a final concentration of 30 μM.
Quantitative Real-Time Reverse Transcription PCR (qRT-PCR)
Relative expression levels of genes for EGFR, VEGF, and IL-8 were
determined by qRT-PCR. Total RNA was extracted from the cells
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reverse-transcribed using the RNA to cDNA EcoDry Premix
(639549; Clontech, Mountain View, CA). The resulting cDNA
was analyzed by qRT-PCR in an iCycler iQ (Bio-Rad). Each reaction
contained 60 ng of cDNA as template, LightCycler 480 SYBR Green
Master Mix (04707516001; Roche, San Francisco, CA), and each of
forward and reverse primers used at 0.4 μM. PCR conditions
included heating for 5 minutes at 95°C, followed by 40 cycles of 30
seconds at 95°C, 30 seconds at 60°C, and 60 seconds at 72°C. The
primer sequences are as follows:
GAPDH: 5 -ACTGCTAGCCGCTTCTTCTT-3 (forward),
5 -GACAAGCTTCCCGTTCTCAG-3 (reverse);
EGFR: 5 -AGGCAGGAGTAACAAGCTCAC-3 (forward),
5 -ATGAGGACATAACAAGCCACC-3 (reverse);
VEGF: 5 -CGAAACCATGAACTTTCTGC-3 (forward),
5 -CCTCAGTGGGCACACACTCC-3 (reverse);
IL8: 5 -AGGGTTGCCAGATGCAATAC-3 (forward),
5 -CCTTGGCCTCAATTTTGCTA-3 (reverse).
A melt curve analysis was performed to ensure specific
amplification. For each target gene, relative levels of expression
were normalized against housekeeping gene signal, GAPDH,
generating Δ cycle threshold (Ct) value (ΔCt = Ct target gene − Ct
reference gene) [41]. The relative gene expression was calculated
according to the formula 2−ΔΔCt, where ΔΔCt = ΔCt experimental
setting − ΔCt control setting [42].
Animal Models
All experiments involving live animals were performed in
accordance of animal protocol approved by The Scripps Research
Institute Animal Care and Use Committee.
Spontaneous Intravasation Model
The chick embryo spontaneous metastasis model was conducted as
described [34,35]. On day 10 of incubation, HT-1080 and HEp-3
tumor variants were grafted at 4 × 105 to 5 × 105 cells, and PC-3
tumor variants were grafted at 2 × 106 cells per chick embryo. To
compensate for reduced levels of cell proliferation after EGFR
silencing, the siEGFR-treated cells were used at 1.3× excess over
control cells. After 5 days (HT-1080 and HEp-3 cells) or 7 days
(PC-3 cells), the primary tumors were excised and weighed. To
determine the numbers of intravasated tumor cells, portions of the
distal CAM were harvested 2 to 3 cm from the edge of the primary
tumor, a distance that is far too great to represent a stromal migration
route for escaping primary tumor cells. Instead, primary tumor cells
arrest in the CAM vasculature after they actively have entered the
angiogenic vessels at the primary tumor site. Therefore, the tumor
cells in the distal CAM represent the intravasated cells that have
disseminated through the vascular routes.
In the case of GFP-labeled cells (e.g., HT-hi/diss cells), the
intravasated cells that had disseminated from the primary tumors
could be visualized in the distal CAM by epifluorescent microscopy
after highlighting CAM vasculature with Rhodamine-conjugated
Lens culinaris agglutinin (LCA; Vector Labs, Burlingame, CA; 25 μg
per embryo). The intravasated cells could be seen as intact cells at
different stages of progression from leaving the CAM vasculature
towards entering the CAM mesoderm (Supplementary Figure S1).
The majority of intravasated cells are visualized as single cells becausespontaneous intravasation occurs through the angiogenic vasculature
that requires some time for development and, therefore, the first sizable
wave of intravasation occurs on day 4 after cell grafting, leaving little
time for proliferation of tumor cells after their extravasation from the
CAM capillaries into the distal CAM stroma. However, the actual
numbers of intravasated cells are relatively low, making their
quantification by microscopy inefficient and statistically unreliable.
Therefore, the levels of intravasation were quantified by extremely
sensitive qPCR detecting human-specific Alu repeats, the method that
has been originally introduced in [43] and extensively used with
modifications in our studies [34,36,37,44,45].
Experimental Metastasis Model
Vascular arrest and tissue colonization assays were performed as
described [35,46]. Tumor cells (5 × 104) were injected directly into
the allantoic vein of chick embryos developing in ovo. Because of the
particularities of blood circulation in the avian embryo, intravenously
(i.v.) inoculated cells are trapped back in the vascular networks of the
CAM, where GFP-tagged tumor cells could be visualized by
epifluorescent microscopy against LCA-contrasted CAM vessels.
After 5 days, i.v. injected tumor cells form multicellular colonies
within CAM stroma, characteristic of metastatic outgrowths
(Supplementary Figure S2). This robust colony formation is in
clear contrast to the single cell status of cells that have spontaneously
intravasated at the primary tumor site and rapidly arrested in the
CAM capillary system (Supplementary Figure S1). To quantify the
levels of vascular arrest and colonization, portions of the CAM were
analyzed by quantitative Alu-qPCR correspondingly at 2 hours and
5 days after cell inoculations.
CAM Microtumor Model
This model is based on the generation of multiple microtumors
developing on the CAM of chicken embryos incubated ex ovo,
allowing for quantitative analyses of primary tumors as whole units
(micro-organs) [37,38]. The GFP-labeled HT-hi/diss cells, non-
treated or transfected with control or EGFR siRNA constructs, were
mixed with 2.2 mg/ml neutralized type I collagen (Becton Dickinson,
Bedford, MA). Nontreated and siCtrl-treated cells were used at
1 × 107 cells/ml, whereas siEGFR- and erlotinib-treated cells were
used at 1.3 × 107 cells/ml. Five 10-μl aliquots of cell-containing
collagen mixtures were placed separately on the top of the CAM
of 10-day-old embryos developing ex ovo (Supplementary Figure
S3). Where indicated, developing microtumors were treated daily
by topical applications of erlotinib (30 μM), VEGF (250 ng/ml),
or purified human neutrophil proMMP-9 (1 μg/ml) delivered in
10 μl of PBS supplemented with 1% DMSO (vehicle). After 5 days,
Rhodamine-conjugated LCA was inoculated i.v. to highlight the
vasculature (25 μg per embryo). Within 5 to 10 minutes, microtumors
were visualized using an Axio Imager (Carl Zeiss, Germany) and images
were acquired with Axiovision Rel. 4.6 software (Carl Zeiss).
Acquisition of 5-μm-thick z-stacks of intratumoral areas allowed us to
confirm that the LCA-highlighted blood vessels indeed were localized
within the primarymicrotumor, as they are surrounded byGFP-labeled
tumor cells within a single optical z-stack (Supplementary Figure S4).
For the size distribution analysis of intratumoral blood vessels, lumen
diameters were quantified using CS5 Adobe Photoshop software in the
images taken at the original magnification of 200× (20× objective ×
10× eyepiece). The numerical data were graphically presented using
GraphPad Prism (GraphPad, SanDiego, CA). To determine the level of
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sections were immunofluorescently stained for neutrophils. Because the
neutrophils are themajor cellular source ofMMP-9 in the avian [44,45]
as well as in mammalian species [47], chick embryo neutrophils were
stained as described [39] with an anti-chicken MMP-9 mAb generated
in our laboratory. The neutrophilic identity of MMP-9–positive
cells was confirmed by their characteristic multilobed nuclei stained
with DAPI.
Quantitative Alu-PCR Analysis (Alu-qPCR)
Quantification of disseminated human tumor cells in chick
embryo CAM was performed with quantitative real-time PCR assay
originally established in the L. Ossowski laboratory [43] and
subsequently used by us with some modifications [34,36,37,45,48].
This assay is based on the quantification of human-specific Alu
sequence repeats in total DNA extracted from the host tissue. Briefly,
genomic DNA was extracted from the CAM tissue using the
Puregene DNA purification system (Qiagen, Minneapolis, MN).
Alu-qPCR was performed to amplify primate-specific Alu repeat
sequences using 10 ng of genomic DNA as a template in a
Bio-RadMyIQLightCycler (Bio-Rad, Hercules, CA). The dsDNA
binding dye SYBR green (Life technologies, Grand Island, NY) was
used for quantification of human tumor cells. The Ct values were
converted into numbers of human cells using a standard curve
generated by spiking constant numbers of chicken cells with serially
diluted human tumor cells.
Measurement of Vascular Permeability
CAM microtumors were generated from unlabeled HT-hi/diss
cells. On day 5, embryos were inoculated with low mol. wt.,
permeable, tetramethylrhodamine (TRITC)-conjugated 155-kDa
dextran (Sigma, Saint Louis, MO). After 1 hour, high mol. wt.,
nonpermeable, fluorescein isothiocyanate (FITC)–conjugated,
2000-kDa dextran (Sigma) was inoculated to displace the permeable
dextran and provide means to measure the total volume of
intratumoral vasculature. Microtumors and intratumoral vasculature
were imaged at fixed exposure times. Then, microtumors were excised and
lysed in 0.3-ml modified radioimmunoprecipitation assay (RIPA) buffer.
Red fluorescence was measured at 576 nm, providing amounts of
tissue-retained permeable TRITC-dextran. Green fluorescence emitted by
FITC-dextran was measured at 516 nm, providing the volume of
perfusable vasculature. Red-to-green fluorescence ratios were determined
for individual microtumors to provide quantification of vascular
permeability independent of total volume of intratumoral vasculature.
Western Blot Analyses and ELISA
Cells were lysed in modified RIPA buffer in the presence of
protease inhibitors. Primary tumors were excised from the CAM,
snap-frozen in liquid nitrogen and ground, and proteins were
extracted in PBS. Protein concentration was determined using the
BCA protein assay from Pierce (Thermo Scientific, Rockford, IL). To
analyze EGFR and pEGFR expression, equal amounts of protein
(20 μg/lane) were reduced and separated on 4% to 20% Tris-glycine
sodium dodecyl sulfate polyacrylamide gel electrophoresis gels (Life
Technologies). After protein transfer, the membranes were blocked in
TBS-Tween 20 containing 5% milk and probed with primary
antibodies. Membranes were incubated with secondary HRP-
conjugated antibodies, and immunoreactive bands were visualized
using SuperSignal West Pico Chemiluminescent Substrate (Pierce).The levels of human VEGF and human IL-8 were analyzed by
capture ELISA kits from Peprotech (900-M10 and 900-M18,
respectively), according to the manufacturer’s instructions. We have
also established that these ELISA kits do not detect any chicken
VEGF or chicken IL-8–like cytokine.
Statistical Analysis
Data processing was conducted using GraphPad Prism. The data
are presented as means ± SEM of percentage changes or fold
differences calculated from the pooled data of independent experi-
ments in which each individual data point was compared with the
mean of corresponding control. Statistical significance was evaluated
using two-tailed unpaired Student t test for P b .05. P values of b .05,
b .01, and b .001 are indicated by *, **, and ***, respectively.
Results
Positive Correlation between Tumor Cell Intravasation and
EGFR Expression
The functional role of EGFR in the early steps of metastasis was
investigated by using hi/diss and lo/diss variants of human HT-1080
fibrosarcoma, HEp-3 head and neck carcinoma, and PC-3 prostate
carcinoma, all of which were selected in vivo for a substantial
differential in intravasation capacity [34,36,37]. When levels of
tumor cell intravasation were compared for primary tumors of similar
size (Figure 1A), the lo/diss variants demonstrated much lower
(HEp-lo/diss) or almost no ability (HT-lo/diss and PC-lo/diss) to
enter into the CAM vasculature retaive to their hi/diss counterparts
(Figure 1B). Notably, when probed for EGFR expression, all three
hi/diss tumor variants demonstrated approximately five-fold more
EGFR protein as compared with their respective lo/diss variants
(Figure 1C ). Together, these data suggested a functional link between
EGFR expression and spontaneous tumor cell dissemination.
Functional Involvement of EGFR in the Early Steps of the
Metastatic Cascade
To verify that EGFR might regulate tumor cell intravasation,
EGFR expression was downregulated in the hi/diss variants with
EGFR siRNA (siEGFR). Efficient silencing of EGFR gene in all three
tumor types was confirmed in comparison with control siRNA
(siCtrl) by qRT-PCR (Figure 2A). Furthermore, Western blot
analysis confirmed the prolonged downregulation of EGFR expres-
sion at the protein level (Figure 2B). The deep and sustained
suppression of EGFR protein (up to and beyond 5 days) allowed us to
use the relatively short-term chick embryo metastasis models to
investigate whether EGFR is functionally involved in specific steps of
the metastatic cascade, namely, in the intravasation step in the
spontaneous metastasis model and in tissue colonization in the
experimental metastasis model.
In agreement with the known regulatory effects of EGFR on cell
proliferation, downregulation of EGFR resulted in a 20% to 25%
decrease in tumor growth in vivo (data not shown). Therefore, to
compensate for this modestly reduced proliferation, the siEGFR-
treated cells were used at 1.3-fold excess over control cells in the
spontaneous metastasis model, allowing for generation of primary
tumors of similar sizes and for separation of the overall effects of
EGFR silencing on tumor growth from its specific effects on tumor
cell intravasation. Despite similar sizes of primary tumors developed
from siCtrl- and siEGFR-treated cells (Figure 2C ), EGFR silencing
(performed with two different sets of siRNA constructs against EGFR
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Figure 1. High levels of tumor cell intravasation correlate with EGFR
overexpression. (A) On day 5 (HT-1080 and HEp-3 variants) or day 7
(PC-3 variants) after cell grafting, primary tumors were excised and
weighed. (B) Tumor cell intravasationwas quantified byAlu-qPCR for
embryosbearing tumors of similar size. (C) Cell lysateswere analyzed
for total EGFR protein byWestern blotting. (Bar graph) Densitometry
of EGFR expression relative to alpha-tubulin (loading control).
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intravasation levels in all three hi/diss tumor types (Figure 2D). Thus,
the ability of tumor cells to disseminate from the primary tumor
through vascular routes positively correlated with the levels of
EGFR expression.In contrast to the spontaneous metastasis model, no significant
effects of EGFR knockdown were observed in the experimental
metastasis model, where tumor cells are inoculated directly into the
circulation, thereby bypassing the early steps of the metastatic cascade.
Downregulation of EGFR produced no significant effects on vascular
arrest of HT-hi/diss cells as measured 2 hours after cell inoculations
(Figure 2E), indicating that EGFR did not affect the initial retention of
this tumor type in the capillary network of the CAM. In addition, no
significant differences were observed in 5-day tissue colonization by
siCtrl- and siEGFR-treated HT-hi/diss cells (Figure 2E). In a similar
fashion, EGFR silencing did not affect either vascular arrest or CAM
colonization of PC-hi/diss or HEp-hi/diss cells (data not shown). This
clear lack of major effects of siRNA treatments on the late stages of
tumor metastasis, i.e., arrest, extravasation, and tissue colonization,
allowed us to exclude major off-target effects of the siRNA constructs
and to conclude that EGFRmight functionally and specifically regulate
an early step of the metastatic cascade, namely, intravasation, which in
turn critically depends on the establishment of tumor-induced
angiogenic vasculature.
EGFR and Development of Intravasation-Sustaining
Angiogenic Vasculature
Because our data suggested that EGFR mechanistically regulates the
ability of tumor cells to spontaneously disseminate through vascular
routes, we investigated whether the negative effect of EGFR silencing on
intravasation could be attributed to specific changes in tumor
angiogenesis. To address this possibility, we used amodified spontaneous
metastasis model involving generation of multiple CAM microtumors.
An extensive neovasculature rapidly develops within these microtumors,
thereby facilitating the process of tumor cell intravasation. The levels of
intravasation are determined in the distal CAM by Alu-qPCR, whereas
microtumors are analyzed in their entirety for the microarchitecture and
permeability of their angiogenic vasculature by epifluorescent micros-
copy [37,38].
CAMmicrotumors of similar size were generated from GFP-tagged
HT-hi/diss cells transfected with control or EGFR siRNA (Supple-
mentary Figure S3), allowing for quantitative comparisons between
two types of treatment. On day 5, epifluorescence microscopy of
microtumors demonstrated that both control and EGFR-silenced
cells triggered strong vascular responses and attracted comparable
numbers of blood vessels converging onto the border of primary
microtumors (Figure 3A, left). However, angiogenic vasculature
analyzed within the tumors at a higher magnification indicated
substantial differences in vessel microarchitecture. Thus, the
vasculature within control microtumors showed well-defined net-
works of lumen-containing blood vessels, whereas EGFR-deficient
microtumors displayed poorly perfused vessels, leading to an
impression of a somewhat less vascularized tumor interior
(Figure 3A, middle and right). However, quantitative analysis
indicated almost equivalent blood vessel density inside both types
of microtumors (Figure 3B). Interestingly, whereas no differences
were observed in larger vessels (30-50 μm in size), control and
siEGFR-deficient tumors manifested a significant differential in
vessels with lumens b30 μm (Figure 3C ). Thus, 60% of blood vessels
within control tumors had lumens with a diameter between 15 and
30 μm compared with only 28% of such vessels in EGFR-deficient
tumors. Reciprocally, 54% of vessels formed within microtumors
developing from siEGFR-treated tumor cells had a lumen diameter of
b15 μm, whereas this very thin vessel category was represented by
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Figure 2. Functional involvement of EGFR in metastasis. Hi/diss cell variants were transiently transfected with control siRNA (siCtrl) and
EGFR-specific siRNA (siEGFR). (A) Forty-eight hours after transfection, levels of EGFR gene expression were analyzed by qRT-PCR and
normalized to GAPDH (1.0). Data are from two or three independent experiments for each tumor type. (B) The levels of total EGFR protein
were analyzed by Western blotting from 2 to 5 days after transfections. Reprobing for tubulin provided loading control. Tumor cells
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30-μm–sized intratumoral vasculature in EGFR-deficient tumors
positively correlated with a significant suppression of intravasation of
EGFR-silenced cells (by 72% of control) (Figure 3D). Importantly,Western blot analysis of excised microtumors confirmed that EGFR
silencing was still sustained at the end of the 5-day-long experiment
(Figure 3E), allowing to link the EGFR expression with tumor cell
intravasation and the microarchitecture of intratumoral blood vessels.
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Figure 3. Tumor cell EGFR regulates the development and microarchitecture of intratumoral intravasation-sustaining angiogenic
vasculature. (A) GFP-labeled HT-hi/diss cells were treated with control (siCtrl) or EGFR (siEGFR) siRNAs and grafted on the CAM of chick
embryos. On day 5, the fluorescently labeled vasculature (red) was examined around and within topical microtumors (green) at an original
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(D) Intravasation levels were quantified by Alu-qPCR and presented as percentage of control (100%) from three independent experiments
involving 18 siCtrl-embryos and 20 siEGFR-embryos. (E) Individual microtumors were analyzed byWestern blotting for total EGFR protein.
Reprobing for alpha-tubulin provided a loading control.
640 EGFR-Mediated Regulation of Tumor Cell Intravasation Minder et al. Neoplasia Vol. 17, No. 8, 2015Together, these data have highlighted a specific role of EGFR that
is different from its direct effects on tumor cells and have suggested a
novel mechanism whereby the activity of EGFR also producesmicroenvironmental cues involved in the induction and development
of an intratumoral angiogenic vasculature capable of sustaining tumor
cell intravasation and dissemination.
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Activity of EGFR
To analyze if the decrease in tumor cell intravasation caused by the
downregulation of EGFR expression involves the suppression of
downstream signaling, we inhibited EGFR tyrosine kinase phosphory-E
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Figure 5. Tumor cell EGFR regulates the permeability of intratumoral intravasation-sustaining vasculature. (A) Microtumors were initiated
from nonlabeled HT-hi/diss cells transfected with control siRNA (siCtrl) or EGFR siRNA (siEGFR). On day 5, embryos were injected with
permeable TRITC-dextran. After 1 hour, embryos were inoculatedwith nonpermeable FITC–dextran and imaged in a fluorescentmicroscope
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fluorescence is depicted monochromatically to highlight TRITC-dextran exudation. (B) Microtumors were lysed, and levels of red and green
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(100%). (Inset) Sustained inhibition of EGFR phosphorylation (pEGFR) in CAM microtumors was validated by Western blotting.
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activated (phosphorylated) EGFR.
Erlotinib-mediated inhibition of EGFR activity did not prevent the
convergence of tumor-adjacent blood vessels towards the border of
the primary microtumors or significantly affect the overall develop-
ment of tumor vasculature (Figure 4A). Furthermore, quantitative
analysis showed no significant difference in the density of angiogenic
vessels inside the microtumors (Figure 4B). However, the vessel size
distribution analysis demonstrated a significant disproportion
between control and erlotinib-treated tumors (Figure 4C ). Thus,
erlotinib substantially reduced the percentage of 15- to 30-μm–sized
blood vessels compared with control group (63% vs 36%). In turn, a
majority of vessels (54%) within erlotinib-treated tumors had a lumen
b15 μm in diameter compared with only 24% in the vehicle-treated
control (Figure 4C ). Therefore, the development patterns of
intratumoral vasculature in erlotinib-treated tumors were very similar
to those observed in EGFR-silenced tumors (Figure 3). Also similar to
EGFR-silenced tumors, erlotinib treatment resulted in a substantial
57% inhibition of spontaneous intravasation compared with vehicle
treatment (Figure 4D). Importantly, whereas erlotinib did not
significantly affect the total EGFR in tumors, Western blot analysis
confirmed a significant inhibition of EGFR activation (Figure 4E ).
These findings indicate that it is not just total EGFR but also
EGFR downstream signaling involving tyrosine phosphorylation
activation that indirectly regulates structural development of
intravasation-sustaining angiogenic vasculature and, in turn, deter-
mines the levels of angiogenesis-dependent tumor cell intravasation.
Tumor Cell EGFR and Permeability of Intratumoral
Angiogenic Vasculature
The demonstrated differential in blood vessel diameter distribution
suggested that although EGFR positively regulates vessel dilation, it
might negatively affect the integrity of endothelial layer. This suggestion
is supported by highly hemorrhagic appearance of microtumors
developing from control siRNA-treated cells in contrast to more benign
pale-looking microtumors originating from EGFR-silenced cells
(Supplementary Figure S3). To verify whether EGFR activity is
responsible for increased vessel leakage, we compared in vivo exudation
of low mol. wt. TRITC-dextran within control HT-hi/diss micro-
tumors versus microtumors that either were generated from EGFR-si-
lenced cells or were treated with erlotinib. Higher exudation levels of
permeable dextran were detected within control microtumors (siCtrl
and vehicle-treated) in contrast to either siEGFR- or erlotinib-treated
tumors (Figure 5, A and D). Fluorometric quantifications confirmed
that both downregulation of EGFR expression and inhibition of EGFR
activity significantly reduced, by more than 50%, the levels of vascular
permeability (Figure 5, B and E). Furthermore, a significant reduction
in tumor cell intravasation (~55% of control) was observed along with
significant downregulation of EGFR expression (Figure 5C ) or
inhibition of EGFR activation (Figure 5F). These vascular permeability
findings indicate that tumor cell EGFR regulates the integrity of the
host vasculature and, therefore, determines its ability to sustain tumor
cell intravasation.
The Underlying Mechanism of EGFR-Mediated Induction
and Development of Intravasation-Sustaining
Angiogenic Vasculature
Induction and maturation of angiogenic vessels within primary
tumors developing in the chick embryo are tightly regulated byVEGF, which becomes bioavailable after its proteolytic release from
the matrix by MMP-9 that in turn, is delivered mainly by
inflammatory neutrophils influxing the primary tumor in response
to tumor-produced IL-8 [45,47]. Because EGFR is known to regulate
the expression of many genes, including VEGF and IL8 [3,49], we
hypothesized that tumor cell EGFR might regulate the development
of an intravasation-sustaining vasculature by controlling production
of IL-8, influx of MMP-9–delivering neutrophils, and bioavailability
of VEGF within the tumor microenvironment.
EGFR silencing in HT-hi/diss cells led to 85% and 50% decreases
in expression of VEGF and IL8 as compared with control
(Figure 6A). Within primary tumors, this significant inhibition of
gene expression was manifested in substantially reduced protein levels
of soluble (bioavailable) human VEGF and also human IL-8, which
correspondingly function as potent inducers of angiogenesis and
chemoattractant of neutrophils in chick embryo model systems [45]
(Figure 6B). Importantly, immunofluorescent analysis of neutrophil
influx determined with a host-specific MMP-9 mAb confirmed that
EGFR silencing also significantly reduced the density of MMP-9–
positive neutrophils (Figure 6B). In the tumor microenvironment,
this inflammatory cell type constitutes the major cellular source of
MMP-9 [45,47,50], the protease that liberates VEGF and makes it
bioavailable for angiogenesis induction [51,52]. Therefore, we have
attempted to restore the diminished levels of VEGF in siEGFR-
treated tumors by the exogenous delivery of purified neutrophil
MMP-9. Importantly, this approach brought the levels of bioavailable
VEGF in EGFR-silenced microtumors to control levels (Figure 6B).
To verify whether diminished levels of intravasation could be
related to the VEGF and neutrophil MMP-9 deficiency caused by the
downregulation of EGFR, we performed a series of in vivo rescue
experiments in which EGFR-silenced tumors were supplemented
with either purified neutrophil MMP-9 or VEGF. Daily topical
applications of either purified neutrophil MMP-9 or VEGF resulted
in the development of more dilated intratumoral vessels resembling
those observed in control conditions (Figure 6C ). Whereas no
significant changes were observed in the overall vessel density under
any test conditions (Figure 6D ), exogenously delivered neutrophil
MMP-9 or VEGF fully restored the proportion of intratumoral blood
vessels with lumen sizes of 15 to 30 μm (Figure 6E ). Importantly, this
change was accompanied by a corresponding diminishment in the
density of vessels of ≤15 μm in size and little or no effect on the larger,
likely more mature vessels of N30 μm in diameter (Figure 6E ).
Furthermore, the siEGFR-mediated reduction of vascular permeabil-
ity was also rescued by both molecular approaches (Figure 6, F and
G). Finally, full restoration to control levels of tumor cell intravasation
was achieved in EGFR-deficient tumors treated with either
neutrophil MMP-9 or VEGF (Figure 6H ), further demonstrating
the molecular link between primary tumor cell intravasation,
neutrophil MMP-9, and bioavailable VEGF
In conclusion, our findings reveal a new mechanism whereby the
levels of tumor cell EGFR can ultimately determine the efficiency of
tumor cell intravasation by controlling the specific microarchitecture
of intratumoral angiogenic vessels through the bioavailable VEGF
that is catalytically liberated by the MMP-9 released from primary
tumor-attracted inflammatory neutrophils.
Discussion
Although being highly specific and potent in preclinical studies, the
EGFR inhibitors are used mainly as additional lines of cancer therapy
644 EGFR-Mediated Regulation of Tumor Cell Intravasation Minder et al. Neoplasia Vol. 17, No. 8, 2015in patients with late-stage cancers [8,13–15,53]. Mutations and
amplifications of certain cancer-related genes along with acquired
EGFR-activating mutations are thought to facilitate cancer resistance
to EFGR-targeted therapies [5,8,9,12,16,54]. However, the relative
inefficiency of EGFR inhibition even in cancers with nonmutated0.0
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vessels is induced in the primary tumor microenvironment through
the EGFR-mediated molecular cross talk between tumor cell–
produced VEGF and IL-8 and neutrophil-delivered MMP-9. This
EGFR-involving complex pathway illuminates a new function of
EGFR, distinct from its direct regulation of tumor cell physiology.
Several lines of evidence allowed us to interconnect the EGFR
overexpressed by primary tumor cells with the capacity of the host
angiogenic vasculature to sustain tumor cell intravasation.
Firstly, the high intravasation potential of three distinct tumor
types, including human fibrosarcoma and two carcinomas, directly
correlated with high levels of EGFR expressed in the corresponding
highly disseminating variants. Secondly, the diminishment of EGFR
expression in all these variants reduced intravasation levels almost to
the levels of the nonintravasating counterparts, thereby suggesting
that EGFR overexpression contributes to spontaneous dissemination
of tumor cells through vascular routes. Importantly, cell dissemina-
tion from primary tumors of similar size was examined in our study
and therefore, siEGFR-induced suppression of intravasation was not
related to diminishment of tumor growth shown in other model
systems [55]. Furthermore, neither vascular arrest nor tissue
colonization was affected by EGFR downregulation during experi-
mental metastasis, strongly indicating that intravasation in the
primary tumor was the most likely step that was altered by EGFR
silencing. These data imply a novel role of EGFR in the metastatic
cascade that is distinct from its known function as a direct regulator of
tumor cell proliferation, motility, stromal invasion, and tissue
colonization [21,23,55–59]. Instead, our data indicate that EGFR
might facilitate tumor cell dissemination by regulating specific aspects
of primary tumor microenvironment. Because tumor cell dissemina-
tion critically depends on the induction of tumor angiogenesis and
establishment of blood vessel networks, we investigated whether
EGFR might be responsible for induction of an intratumoral
neovasculature capable of sustaining tumor cell intravasation.
The notion that EGFR could be a critical regulator of
intravasation-sustaining vasculature during early tumor development
was investigated by using our recently established model uniquely
allowing for quantification of intravasation in tandem with quanti-
tative analyses of vascular permeability and microarchitecture in
tumors treated as whole functioning micro-organs [37,38]. Herein,
the functional contribution of EGFR protein and its downstream
signaling activity to intravasation was interrogated by two approaches,
namely, by siRNA-mediated downregulation of EGFR expression and
by erlotinib-mediated inhibition of EGFR tyrosine kinase activity.Figure 6. EGFR-mediated development of intravasation-sustaining
neutrophil MMP-9. A) Gene expression of VEGF and IL8 was determ
difference over GAPDH levels (1.0) calculated from two independent
HT-hi/diss cells. Individual siEGFR microtumors were treated daily with
On day 5, soluble (PBS-extracted) VEGF and IL-8 were quantified in mic
(100%) calculated from three independent experiments. The density
immunofluorescent staining ofmicrotumors forMMP-9, a specificmarke
isolated from the chick embryo and immunostainedwithmAb specific fo
nuclei, characteristic of neutrophils. (C–G) Fraction of siEGFRmicrotumo
volume of vehicle (10 μl). On day 5, microtumors were analyzed for ove
diameter (E), and tumor vasculature permeability (F and G) as describe
employing eight embryos for each treatment condition (49 siCtrl tumors
and 48 siEGFR tumors treated with VEGF). (H) Intravasation levels were q
for each treatment condition from two independent experiments involvin
with neutrophil MMP-9, and 15 siEGFR-embryos treated with VEGF.These independent approaches resulted in remarkably similar patterns
of intravasation inhibition, indicating that it is the activity of EGFR
that ultimately determines the levels of tumor cell intravasation.
Specifically, silencing and inhibition of EGFR caused a dramatic
difference in the microarchitecture of intratumoral vessels between
the control and EGFR-downregulated or EGFR-inhibited micro-
tumors. Whereas no significant EGFR-dependent effects were
observed in the density of blood vessels converging onto primary
tumors, both the downregulation of tumor cell EGFR and the
inhibition of EGFR activity led to development of weak and collapsed
intratumoral vessel networks. In particular, the size distribution
analysis indicated that EGFR activity was critical for the dominant
appearance of intermediate-sized vessels with lumen diameters
between 15 and 30 μm and that presence of this particular vessel
category coincided with high levels of intravasation. In fact, the
reciprocal disappearance of such intratumoral vessels from EGFR-
deficient tumors allowed us to delineate this distinct class of
angiogenic vessels (with lumens between 15 and 30 μm in diameter)
as capable of sustaining tumor cell intravasation. Noteworthy, the
larger vessels (N30 μm in diameter) were not affected by EGFR
modulation, indicating that these more mature or co-opted blood
vessels neither respond to anti-EGFR therapy nor facilitate tumor cell
intravasation. Most importantly, the altered, collapsed structure of
blood vessels in EGFR-silenced or EGFR-inhibited tumors closely
correlated with significantly reduced levels of tumor cell intravasation.
In addition to the microarchitecture of intratumoral angiogenic
vessels, we showed that EGFR activity also regulated their
permeability. Thus, high levels of dextran exudation were observed
in EGFR-competent microtumors harboring mostly middle-sized
vessels (≥15-30 μm), pointing to this category of intratumoral
neovessels as permeable and accessible for tumor cell penetration
because these vessels already posses a lumen that can readily
accommodate an intravasating tumor cell but have not yet developed
a hard-to-disrupt, nonleaky endothelial barrier. Decreased perme-
ability of intratumoral vasculature was observed both in EGFR-
silenced tumors and in tumors treated with EGFR inhibitor erlotinib.
Whereas erlotinib can directly affect the development of angiogenic
vasculature through the endothelial cell EGFR and cause vascular
normalization [60], the silencing of EGFR in the primary tumor cells
suggested that EGFR could modulate tumor microenvironment
through regulating the production of VEGF, a critical angiogenesis
inducer and important regulator of blood vessel permeability.
Consistent with the EGFR-mediated regulation of VEGF expression
and antiangiogenic effects of EGFR inhibition [23,61–63], wevasculature involves the tumor cell-produced VEGF released by
ined by RT-qPCR in siCtrl or siEGFR HT-hi/diss cells. Data are fold
experiments. (B) Microtumors were initiated from siCtrl and siEGFR
10 ng purified neutrophil MMP-9 or equal volume of vehicle (10 μl).
rotumor extracts by a capture ELISA. Data are percentage of control
of neutrophils was analyzed in two independent experiments by
r ofMMP-9–loaded neutrophils. Imageon the right depicts neutrophils
r chickenMMP-9 (pink). DAPI staining (light blue) highlightsmultilobed
rswas treated dailywith 10 ngneutrophilMMP-9, 25 ngVEGF, or equal
rall appearance of the vasculature (C), blood vessel density (D), vessel
d in Figures 3 and 5. Data are from three independent experiments
, 49 siEGFR tumors, 22 siEGFR tumors treated with neutrophil MMP-9,
uantified by Alu-qPCR and presented as percentage of control (100%)
g 14 siCtrl-embryos, 14 siEGFR-embryos, 14 siEGFR-embryos treated
646 EGFR-Mediated Regulation of Tumor Cell Intravasation Minder et al. Neoplasia Vol. 17, No. 8, 2015confirmed that downregulation of EGFR led to a significant
diminishment of VEGF expression in cultured tumor cells. More
importantly, these negative effects of EGFR inhibition were linked to
diminishment of soluble VEGF protein within microtumors,
allowing us to associate for the first time EGFR activity to the
bioavailability of VEGF in the primary tumor microenvironment.
Whereas VEGF directly determines the levels of blood vessel
permeability [64], the cancer cell–produced IL-8 determines the
levels of inflammatory neutrophil influx into primary tumors
[45,65,66]. In agreement with the negative effects of EGFR
inhibition on IL-8 production [3,23], EGFR downregulation
significantly reduced IL-8 gene and protein expression in primary
tumors. Not surprisingly, the influx of tumor-infiltrating MMP-9–
loaded neutrophils responding to their major attractant, IL-8, was also
reduced. These results strongly suggest that the diminished levels of
soluble VEGF in EGFR-deficient tumors might be linked to
deficiency of neutrophil MMP-9, the critical proteinase that makesFigure 7. EGFR-mediated regulation of VEGF-dependent tumor ang
overexpressed on aggressive tumor cells interacts with one of its s
phosphorylation of its cytoplasmic domain (1). Through intracellu
expression of many genes, including VEGF and IL8 (2). Increased prod
requires proteolytic liberation to become bioavailable and gain an an
the major neutrophil chemoattractant, leads to influx of inflammato
major receptor of IL-8. Tumor-infiltrating neutrophils, in turn, constitut
Neutrophil MMP-9 is prestored in the secretory granules as a proMM
still largely unknown mechanisms that possibly involve binding of pr
extremely high affinity to collagenous fibrils, digests partially denatur
VEGF becomes a bioavailable factor capable of binding to the V
dimerization-dependent signaling (6). Activated endothelial cells then
Relatively high levels of VEGF are required for induction of lumen for
hand, high levels of VEGF reduce the integrity of the endothelial barr
facilitate tumor cell penetration into the inner space of an angiogenic
the above-described chain of events, leading to detrimental condition
tumor cell intravasation.VEGF bioavailable by releasing it from the tumor-associated matrix
[45,50,51]. This suggestion was confirmed by a rescuing approach
whereby an exogenous delivery of purified neutrophil MMP-9 fully
restored the levels of soluble VEGF in the EGFR-silenced tumors.
Together, our findings illuminated a complex interplay between
EGFR-regulated production of VEGF and IL-8 by tumor cells and
IL-8–mediated attraction of neutrophils delivering the VEGF-
liberating protease MMP-9. These multifaceted relationships were
validated when exogenous delivery to EGFR-deficient tumors of
either VEGF or neutrophil MMP-9 fully restored the intratumoral
vessel architecture and vascular permeability coordinately with the
rescue of tumor cell intravasation. Furthermore, specific rescue
approaches employing purified forms of components usually found in
primary tumors, also corroborated our findings that the deficiency in
tumor cell EGFR expression or EGFR activity modifies tumor
microenvironment through diminished influx of MMP-9–delivering
neutrophils and reduced bioavailability of VEGF. The insufficientiogenesis. The schematic presents a mechanism whereby EGFR
oluble ligand(s), which causes dimerization of EGFR and tyrosine
lar signaling pathways, the functionally activated EGFR induces
uction of VEGF results in accumulation of matrix-bound VEGF that
giogenesis-inducing capacity. Increased expression of IL-8 protein,
ry neutrophils (3) because they express high levels of CXCR2, the
e the major cellular source of MMP-9, the VEGF-liberating protease.
P-9 zymogen which upon neutrophil degranulation is activated by
oMMP-9 to collagenous matrices (4). Activated MMP-9, which has
ed matrix fibrils, thereby liberating matrix-bound VEGF (5). Soluble
EGFR on the endothelial cell, causing VEGFR dimerization and
form capillaries and lumen-containing angiogenic blood vessels (7).
mation and also for the maintenance of lumen space. On the other
ier, thus assuring certain levels of endothelial layer permeability to
vessel. Silencing of EGFR or inhibition of its activity would prevent
s for development of angiogenic vasculature capable of sustaining
Neoplasia Vol. 17, No. 8, 2015 EGFR-Mediated Regulation of Tumor Cell Intravasation Minder et al. 647levels of bioavailable VEGF as a result of dampened levels of EGFR,
IL-8, neutrophil influx, and neutrophil MMP-9 would significantly
impair VEGFR-mediated activation of the sprouting endothelial cells.
Consequently, this impairement would prevent formation of the
angiogenic vessels with sizable 15- to 30-μm lumens, which appear to
be required to provide a sufficient space for intravasating tumor cells.
Alternatively, the angiogenic vessels might be formed but not be
dilated enough or be permeable enough for tumor cell penetration
through the endothelial cell barrier. In our study, this scenario is
consistent with the observed accumulation of small-sized blood
vessels in EGFR-silenced tumors and apparent insensitivity of larger,
possibly co-opted vessels to diminished levels of VEGF in the tumor
microenvironment. Therefore, the overall functional significance of
tumor-expressed EGFR in regulation of tumor angiogenesis, vascular
structure, and vessel integrity strongly implicates for the first time a
specific mechanism involving EGFR in the development of a distinct
intravasation-sustaining intratumoral vasculature (Figure 7).
Our study also highlights some mechanistic checkpoints, which
could explain a relative inefficiency of anti-EGFR therapies. First,
vascular dissemination of tumor cells responsible for metastatic
disease can occur much earlier than the time frame when anti-EGFR
therapy is initiated in most cancer patients. Therefore, the success of
any anti-EGFR therapy might be limited to the early stages of cancer
progression when EGFR inhibitors would effectively target the
young, developing intratumoral vasculature, which provides the
conduits for early-on primary tumor cell dissemination. In contrast,
more mature vessels could be stabilized with protective pericytes that
would protect the underlying endothelium from either too high or
too low concentrations of VEGF [67,68]. These considerations can
provide additional reasons for the modest success of anti-EGFR
inhibitors used in clinic for late-stage cancer patients, whose primary
tumors might have larger proportion of co-opted blood vessels that
are less sensitive to diminishment of VEGF caused by EGFR
therapeutics. Second, our data indicate that tumor cell intravasation
could be sensitive even to moderate diminishment of EGFR-
dependent production of VEGF and IL-8 proteins, IL-8–dependent
neutrophil influx, and ensuing delivery of neutrophil MMP-9
releasing matrix-bound VEGF. The dependence of intravasation-
sustaining intratumoral vessels on VEGF that regulates their
permeability and integrity could be reflected in increased benefits
of anti-EGFR therapies combined with anti-VEGF agents, a
combinatorial approach currently used in clinic, albeit mainly for
late-stage cancers [49,69–71]. Furthermore, our newly established
mechanism suggests that additional beneficiary effects may come
from combining EGFR-targeted therapy with anti–IL-8 and/or
anti-inflammatory drugs [72]. These synergistic approaches could
prevent the EGFR-induced delivery of MMP-9, a potent liberator of
VEGF at the site of primary tumor development and a critical
modulator of metastatic niches at the secondary sites [73–75]. In
conclusion, the findings from this study indicate an EGFR/IL-8/
neutrophil MMP-9/VEGF pathway as a valid axis to functionally
compromise the intratumoral vasculature during anticancer therapy.
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